Targeting Elevated GnRH Pulsatility to Treat Polycystic Ovary Syndrome

Neurokinin 3 receptor antagonism ameliorates key metabolic features in a hyperandrogenic PCOS mouse model

(2021) Irene E Sucquart et al.   ENDOCRINOLOGY

Polycystic ovary syndrome revisited: an interactions network approach

(2021) Styliani A. Geronikolou et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome

(2021) Graeme L Fraser et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Altered expression of the kisspeptin/KISS1R and neurokinin B/NK3R systems in mural granulosa and cumulus cells of patients with polycystic ovarian syndrome

(2018) Victor Blasco et al.   JOURNAL OF ASSISTED REPRODUCTION AND GENETICS

Neuroendocrine androgen action is a key extraovarian mediator in the development of polycystic ovary syndrome

(2017) Aimee S. L. Caldwell et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Neurokinin B Receptor Antagonism in Women With Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial

(2016) Jyothis T. George et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The NK3 Receptor Antagonist ESN364 Suppresses Sex Hormones in Men and Women

(2016) Graeme L. Fraser et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM